Limay Biosciences

Limay Biosciences is an Argentina-based biotechnology startup that develops rapid, low-cost, and portable molecular diagnostic solutions. Founded in 2020, the company leverages a combination of CRISPR-based detection, isothermal nucleic acid amplification, microfluidics, and embedded AI to create diagnostic tools that deliver results in minutes rather than days. By decentralizing molecular testing, the company aims to move diagnostics from centralized laboratories to the point of need, making advanced analysis more accessible and enabling faster clinical decision-making. Their proprietary technology, known as SMART, is designed to be highly sensitive and specific while remaining affordable and easy to use.

The company's primary focus is on addressing critical healthcare and agricultural challenges, with their most advanced product being a rapid dengue virus diagnostic kit. This kit identifies all four variants of the virus from a blood sample in less than two hours and has been developed for large-scale production through a partnership with Infinity Pharma. Beyond dengue, Limay Biosciences is actively researching and developing diagnostic solutions for severe bacterial infections, antimicrobial resistance, and agtech applications, such as identifying genetically modified seeds. By securing strategic investment from organizations like CITES and SF500, the company is scaling its research and development operations to bring these innovations to both local and international markets.